Has Guardant Health Lived Up to the Hype?
Humans have known for a long time that a person's blood can tell us a lot about their health. In 1628, William Harvey discovered how blood circulated through the body, and in 1665 the first successful blood transfusion was performed with dogs. It would be almost another 150 years before a successful transfusion was performed on a person. Today, scientists are using our understanding of blood to investigate cancers and take a more personalized approach to disease treatment.
Guardant Health (NASDAQ: GH) went public with a popular IPO in 2018, soaring 70% on its first day of trading. The oncology company has continued its ascent, rising by about 230% since. The excitement over blood tests that can detect cancers and lead to personalized treatments has not abated. Companies such as Freenome, Thrive, and Grail have joined Guardant on the hunt for tiny fragments of cancer DNA in patients' blood. But has Guardant Health capitalized on widespread excitement and built a large-enough foothold in the industry?
Image source: Getty Images.
Source Fool.com
